Doxifluridine API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Doxifluridine is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Doxifluridine or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Doxifluridine API 3094-09-5?

Description:
Here you will find a list of producers, manufacturers and distributors of Doxifluridine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Doxifluridine 
Synonyms:
1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil , 5-fluoro-5'-deoxyuridine , 5'-deoxy-5-fluorouridine , 5'-DFUR , Doxifluridina , Doxifluridinum  
Cas Number:
3094-09-5 
DrugBank number:
DB12947 
Unique Ingredient Identifier:
V1JK16Y2JP

General Description:

Doxifluridine, identified by CAS number 3094-09-5, is a notable compound with significant therapeutic applications. Doxifluridine has been investigated for the treatment of Stomach Cancer.

Classification:

Doxifluridine belongs to the class of organic compounds known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives, classified under the direct parent group 5'-deoxyribonucleosides. This compound is a part of the Organic compounds, falling under the Nucleosides, nucleotides, and analogues superclass, and categorized within the 5'-deoxyribonucleosides class, specifically within the None subclass.

Categories:

Doxifluridine is categorized under the following therapeutic classes: Antimetabolites, Antineoplastic Agents, Appetite Stimulants, Central Nervous System Agents, Central Nervous System Stimulants, Deoxyribonucleosides, Deoxyuridine, Fluoropyrimidines, Fluorouracil and prodrugs, Immunologic Factors, Immunosuppressive Agents, Isomerism, Noxae, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Pyrimidine Nucleosides, Pyrimidines, Toxic Actions. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Doxifluridine is a type of Antimetabolites


Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.

One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.

Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.

Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.

In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.